Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

NCT01604889 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01604889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01604889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
March 29, 2012
Completion date
January 20, 2017
Enrollment
50 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma